JPH0237358B2 - 55MECHIRUU77JECHIRUAMINOOSSTORIAZORO * 1 * 55A * PIRIMIJINNOSEISEIHO - Google Patents
55MECHIRUU77JECHIRUAMINOOSSTORIAZORO * 1 * 55A * PIRIMIJINNOSEISEIHOInfo
- Publication number
- JPH0237358B2 JPH0237358B2 JP13796482A JP13796482A JPH0237358B2 JP H0237358 B2 JPH0237358 B2 JP H0237358B2 JP 13796482 A JP13796482 A JP 13796482A JP 13796482 A JP13796482 A JP 13796482A JP H0237358 B2 JPH0237358 B2 JP H0237358B2
- Authority
- JP
- Japan
- Prior art keywords
- trapidil
- crude
- solution
- present
- sulfur compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 238000000034 method Methods 0.000 claims description 20
- 150000003464 sulfur compounds Chemical class 0.000 claims description 16
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 230000001603 reducing effect Effects 0.000 claims description 4
- POFDSYGXHVPQNX-UHFFFAOYSA-N triazolo[1,5-a]pyrimidine Chemical compound C1=CC=NC2=CN=NN21 POFDSYGXHVPQNX-UHFFFAOYSA-N 0.000 claims 1
- GSNOZLZNQMLSKJ-UHFFFAOYSA-N Trapidil Chemical compound CCN(CC)C1=CC(C)=NC2=NC=NN12 GSNOZLZNQMLSKJ-UHFFFAOYSA-N 0.000 description 31
- 229960000363 trapidil Drugs 0.000 description 31
- 239000000243 solution Substances 0.000 description 13
- 238000002835 absorbance Methods 0.000 description 10
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 7
- 239000008096 xylene Substances 0.000 description 7
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- QGJOPFRUJISHPQ-UHFFFAOYSA-N Carbon disulfide Chemical compound S=C=S QGJOPFRUJISHPQ-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 239000010410 layer Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000012044 organic layer Substances 0.000 description 3
- 239000003960 organic solvent Substances 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 2
- -1 5-methyl-7-substituted-s-triazolo[1,5-a]pyrimidine Chemical group 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 239000011541 reaction mixture Substances 0.000 description 2
- TXHUHDDZTWDOAJ-QPJJXVBHSA-N (e)-n,n-diethylbut-2-enamide Chemical compound CCN(CC)C(=O)\C=C\C TXHUHDDZTWDOAJ-QPJJXVBHSA-N 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- INVVMIXYILXINW-UHFFFAOYSA-N 5-methyl-1h-[1,2,4]triazolo[1,5-a]pyrimidin-7-one Chemical compound CC1=CC(=O)N2NC=NC2=N1 INVVMIXYILXINW-UHFFFAOYSA-N 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 229910004878 Na2S2O4 Inorganic materials 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical class OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- SRNKZYRMFBGSGE-UHFFFAOYSA-N [1,2,4]triazolo[1,5-a]pyrimidine Chemical compound N1=CC=CN2N=CN=C21 SRNKZYRMFBGSGE-UHFFFAOYSA-N 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 125000004414 alkyl thio group Chemical group 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000003218 coronary vasodilator agent Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000002425 crystallisation Methods 0.000 description 1
- 230000008025 crystallization Effects 0.000 description 1
- 239000012024 dehydrating agents Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 150000008282 halocarbons Chemical class 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 125000001475 halogen functional group Chemical group 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- SRRKNRDXURUMPP-UHFFFAOYSA-N sodium disulfide Chemical compound [Na+].[Na+].[S-][S-] SRRKNRDXURUMPP-UHFFFAOYSA-N 0.000 description 1
- JVBXVOWTABLYPX-UHFFFAOYSA-L sodium dithionite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])=O JVBXVOWTABLYPX-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- HYHCSLBZRBJJCH-UHFFFAOYSA-M sodium hydrosulfide Chemical compound [Na+].[SH-] HYHCSLBZRBJJCH-UHFFFAOYSA-M 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
Landscapes
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Description
本発明は、5−メチル−7−ジエチルアミノ−
s−トリアゾロ〔1,5−a〕ピリミジン(以
下、トラピジルと略称する。)の精製方法に関す
る。
トラピジルは冠拡張剤として優れた薬効を有す
ることが知られている。このトラピジルを製造す
る方法は、例えば英国特許第1148629号、特開昭
56−79674号、特開昭56−108772号などの公報明
細書に提案されている。またこれらの先行技術文
献には、粗製のトラピジルを各種の溶剤を用い
て、抽出、再結晶などの諸操作を繰り返すことに
よつて精製しようとする試みも記載されている。
しかしながら、これらに具体的に開示されている
方法によつても粗製のトラピジルは充分には精製
されず、例えば得られるトラピジルが着色不純物
で汚染されていたり、あるいは充分に純度が高く
なく、医薬品として供するには不充分な品質であ
ることが多い。
本発明者らは、これらの現状に鑑み、粗製のト
ラピジルから医薬品として適合し得る高品質でか
つ高純度の精製品を収率よく得る方法について鋭
意検討を重ねた結果、精製のトラピジルを特定の
硫黄化合物で接触処理することにより前記目的を
達成できることを見出し、本発明の方法に到達し
たものである。
本発明を概説すれば、本発明は、粗製のトラピ
ジルと還元作用を有する硫黄化合物とを、水の存
在下に接触させることを特徴とする該化合物の精
製法、を要旨とするものである。
本発明の方法において使用される粗製のトラピ
ジルは、如何なる方法で製造されたものであつて
もよい。例えば7位がハロゲン、メルカプト基、
アルキルメルカプト基、アルコキシル基等で置換
された5−メチル−7−置換−s−トリアゾロ
〔1,5−a〕ピリミジンとジエチルアミンを反
応させる方法、N,N−ジエチル酢酸アミドと3
−アミノ−1,2,4−トリアゾールを脱水剤の
存在下で反応させる方法3−ハロ(またはアルコ
キシ)クロトン酸ジエチルアミドと3−アミノ−
1,2,4−トリアゾロールを縮合剤の存在下で
反応させる方法などを例示することができるが、
本発明の方法は、これらの方法に特定されない。
本発明の方法において、使用される還元作用を
有する硫黄化合物として具体的には、Na2S、
Na2S2、NaHS、NaHSO3、Na2SO3、Na2S2O4、
Na2S2O3、Zn(HSO3)およびロンガリツトCな
どを例示することができる。これらの硫黄化合物
のうちでは、NaHSO3、Na2SO3などの金属亜硫
酸塩化合物を使用すると精製効果が著しいので好
適である。これらの硫黄化合物の使用量は粗製の
トラピジルに対して通常1〜50重量%、好ましく
は5〜20重量%の範囲である。
本発明の方法において、前記粗製トラピジルと
前記硫黄化合物との接触処理は水の存在下に実施
することが必要である。その接触の際の水の存在
割合は、前記硫黄化合物に対して通常5ないし
200重量倍、好ましくは20ないし100重量倍の範囲
であり、前記硫黄化合物が溶解する量であること
が好適である。もちろん、前記粗製トラピジルを
水溶液または水含有溶液の形態で使用した場合に
は、改めて水を加えることは必ずしも必要でな
い。
本発明の方法において、前記粗製トラピジルと
前記硫黄化合物とを接触させる際には、該粗製の
トラピジルは溶液状態であることが好適であり、
水溶液の状態であつてもよいし、還元作用を有す
る硫黄化合物に対して不活性な有機溶媒の溶液の
状態であつてもよいが、水溶液の状態であること
がとくに好ましい。該粗製のトラピジルを前記有
機溶媒溶液の形態で使用する際には、該溶液は非
水溶性溶媒の溶液であることが好ましい。
有機溶媒として具体的には、ヘキサン、ベンゼ
ン、トルエン、キシレンなどの炭化水素、クロロ
ホルム、エチレンジクロライドなどのハロゲン化
炭化水素、メタノール、エタノールなどのアルコ
ールあるいは二硫化炭素などの広範囲の溶媒を例
示することができる。これらの溶媒は、2種以上
の混合溶媒として使用することもできる。
本発明の方法において、前記粗製のトラピジル
の溶液、前記硫黄化合物、水および必要に応じて
溶媒からなる混合物は、通常撹拌または振とう条
件下に接触させられる。接触処理の際の温度はと
くに限定されないが、通常10℃ないし150℃、好
ましくは20℃ないし90℃の範囲である。接触処理
の際の時間は伊用する硫黄化合物の種類および温
度によつて異なるが、通常は0.5ないし30時間、
好ましくは1.0ないし6時間の範囲で充分の精製
効果を挙げることができる。
本発明の方法によれば、硫黄化合物と接触させ
た後の混合物に通常の抽出、晶析操作を施すこと
によつて医薬品として適合し得る着色度の少ない
高品質、かつ高純度のトラピジルを得ることがで
きる。
次に実施例により本発明を具体的に説明する。
なお、実施例に示したトラピジルの吸光度E1%
1cm(450nm)は、1cmのセルを用いたトラピジ
ルの1重量%水溶液の波長450nmの吸光度を表
わし、E0.667
1cm(427nm)は1cmのセルを用いた
トラピジルの0.667重量%水溶液の波長427nmで
の吸光度である。
参考例 1
〔粗製トラピジルの調製法〕
5−メチル−7−ヒドロキシ−s−トリアゾロ
〔1,5−a〕ピリミジン300.8gとエチレンジク
ロライド750gおよびオキシ塩化リン366gを窒素
気流下に90℃〜88℃で5時間加熱撹拌した。この
溶液を水1400gと重炭酸ナトリウム840gの混合
物に20℃で滴下して、同温度でさらに1.0時間撹
拌した。この反応混合物にクロロホルム1700gを
加えて有機層と水層とに分液した。有機層にジエ
チルアミン322gを30℃で滴下して、滴下終了後
50℃で1.0時間撹拌した。次いでこの反応混合物
を水500gで洗浄して有機層を乾固したところ粗
製のトラピジルが321g得られた(純度95.8%)。
これはトラピジルの収率75%に相当する。
実施例 1
粗製のトラピジル〔E1%
1cm(450nm)0.611、
純度95.8%〕5.0gをキシレン20gに溶解させて
NaHSO30.5gを含む水溶液5.0gを加え、80℃で
1.0時間撹拌し、キシレン層からキシレンを留去
したところ純度98%のトラピジルが4.9g得られ、
このトラピジルの吸光度E1%
1cm(450nm)は
0.320であつた。
比較例 1
実施例1においてNaHSO3を加えることなく
実施例1と同様の操作を行つた。その結果、純度
98%のトラピジルが4.75g得られ、その吸光度E
1%
1cm(450nm)は0.600であつた。
実施例 2〜9
表1に示した吸光度の粗製トラピジル50gを水
100gに溶解した、この溶液に表1に示した種々
の硫黄化合物5gを加えて表1に示した温度で3
時間撹拌したのち、この溶液の吸光度を測定した
ところ表1の結果が得られた。
The present invention provides 5-methyl-7-diethylamino-
The present invention relates to a method for purifying s-triazolo[1,5-a]pyrimidine (hereinafter abbreviated as trapidil). Trapidil is known to have excellent medicinal efficacy as a coronary dilator. This method of producing trapidil is described in, for example, British Patent No. 1148629, Japanese Patent Application Publication No.
This method has been proposed in publications such as No. 56-79674 and JP-A-56-108772. These prior art documents also describe attempts to purify crude trapidil by repeating various operations such as extraction and recrystallization using various solvents.
However, even by the methods specifically disclosed in these documents, crude trapidil is not purified sufficiently, and for example, the resulting trapidil is contaminated with colored impurities or is not of high enough purity to be used as a pharmaceutical product. They are often of insufficient quality to serve as food. In view of these current circumstances, the present inventors have conducted intensive studies on methods for obtaining high-quality, highly purified purified products suitable for use as pharmaceuticals from crude Trapidil in a high yield. The inventors have discovered that the above object can be achieved by contact treatment with a sulfur compound, and have arrived at the method of the present invention. To summarize the present invention, the gist of the present invention is a method for purifying crude trapidil and a sulfur compound having a reducing action, which is characterized by contacting the compound in the presence of water. The crude trapidil used in the method of the present invention may be produced by any method. For example, the 7th position is a halogen, a mercapto group,
A method for reacting 5-methyl-7-substituted-s-triazolo[1,5-a]pyrimidine substituted with an alkylmercapto group, alkoxyl group, etc. with diethylamine, and N,N-diethyl acetate amide and 3
-Method of reacting amino-1,2,4-triazole in the presence of a dehydrating agent 3-Halo (or alkoxy)crotonic acid diethylamide and 3-amino-
Examples include a method of reacting 1,2,4-triazole in the presence of a condensing agent, etc.
The method of the present invention is not limited to these methods. In the method of the present invention, the sulfur compounds having a reducing action used include Na 2 S,
Na2S2 , NaHS , NaHSO3 , Na2SO3 , Na2S2O4 ,
Examples include Na 2 S 2 O 3 , Zn (HSO 3 ), and Rongarit C. Among these sulfur compounds, it is preferable to use metal sulfite compounds such as NaHSO 3 and Na 2 SO 3 because they have a remarkable purification effect. The amount of these sulfur compounds used is usually 1 to 50% by weight, preferably 5 to 20% by weight based on crude trapidil. In the method of the present invention, it is necessary to carry out the contact treatment of the crude trapidil and the sulfur compound in the presence of water. The ratio of water present during the contact is usually 5 to 5 to the sulfur compound.
The amount is preferably in the range of 200 times by weight, preferably 20 to 100 times by weight, and the amount is preferably such that the sulfur compound is dissolved. Of course, when the crude trapidil is used in the form of an aqueous solution or a water-containing solution, it is not necessarily necessary to add water again. In the method of the present invention, when the crude trapidil and the sulfur compound are brought into contact, it is preferable that the crude trapidil is in a solution state,
It may be in the form of an aqueous solution or a solution of an organic solvent inert to the sulfur compound having a reducing action, but it is particularly preferable to be in the form of an aqueous solution. When the crude trapidil is used in the form of a solution in the organic solvent, the solution is preferably a solution in a non-aqueous solvent. Specific examples of organic solvents include a wide range of solvents such as hydrocarbons such as hexane, benzene, toluene, and xylene, halogenated hydrocarbons such as chloroform and ethylene dichloride, alcohols such as methanol and ethanol, and carbon disulfide. Can be done. These solvents can also be used as a mixed solvent of two or more. In the method of the present invention, a mixture consisting of the solution of crude trapidil, the sulfur compound, water and optionally a solvent are brought into contact, usually under stirring or shaking conditions. The temperature during the contact treatment is not particularly limited, but is usually in the range of 10°C to 150°C, preferably 20°C to 90°C. The contact treatment time varies depending on the type of sulfur compound used and the temperature, but is usually 0.5 to 30 hours.
A sufficient purification effect can be obtained preferably within a range of 1.0 to 6 hours. According to the method of the present invention, by subjecting the mixture to contact with a sulfur compound and subjecting it to conventional extraction and crystallization operations, trapidil of high quality and purity with a low degree of coloring and suitable as a pharmaceutical product is obtained. be able to. Next, the present invention will be specifically explained with reference to Examples. In addition, the absorbance of trapidil E1% 1cm (450nm) shown in the example represents the absorbance of a 1% by weight aqueous solution of trapidil at a wavelength of 450nm using a 1cm cell, and E0.667 1cm (427nm) represents the absorbance at a wavelength of 450nm using a 1cm cell. This is the absorbance at a wavelength of 427 nm of the 0.667% by weight aqueous solution of trapidil used. Reference Example 1 [Preparation method of crude trapidil] 300.8 g of 5-methyl-7-hydroxy-s-triazolo[1,5-a]pyrimidine, 750 g of ethylene dichloride, and 366 g of phosphorus oxychloride were heated at 90°C to 88°C under a nitrogen stream. The mixture was heated and stirred for 5 hours. This solution was added dropwise to a mixture of 1400 g of water and 840 g of sodium bicarbonate at 20°C, and the mixture was further stirred at the same temperature for 1.0 hour. 1700 g of chloroform was added to this reaction mixture to separate it into an organic layer and an aqueous layer. Add 322g of diethylamine to the organic layer at 30°C, and after the addition is complete.
Stirred at 50°C for 1.0 hour. The reaction mixture was then washed with 500 g of water and the organic layer was dried to obtain 321 g of crude trapidil (purity 95.8%).
This corresponds to a 75% yield of trapidil. Example 1 Crude trapidil [E1% 1 cm (450 nm) 0.611,
Dissolve 5.0g of purity 95.8% in 20g of xylene.
Add 5.0 g of an aqueous solution containing 0.5 g of NaHSO 3 and heat at 80°C.
After stirring for 1.0 hour, xylene was distilled off from the xylene layer to obtain 4.9 g of trapidil with a purity of 98%.
The absorbance of trapidil is E1% 1cm (450nm).
It was 0.320. Comparative Example 1 The same operation as in Example 1 was carried out without adding NaHSO 3 . As a result, purity
4.75 g of 98% trapidil was obtained, and its absorbance E
1% 1cm (450nm) was 0.600. Examples 2 to 9 50g of crude Trapidil with the absorbance shown in Table 1 was added to water.
5 g of the various sulfur compounds shown in Table 1 were added to this solution dissolved in 100 g of the sulfur compound at the temperature shown in Table 1.
After stirring for a period of time, the absorbance of this solution was measured, and the results shown in Table 1 were obtained.
【表】【table】
【表】
実施例 10
粗製のトラピジル〔E0.667
1cm(427nm)1.00〕
50gを100gの水に溶解させてNaHSO35.0gを加
え、80℃で5.0時間撹拌したところこの溶液の吸
光度E0.667
1cm(427nm)は0.220に減じた。次いで
キシレン200gを加えて80℃で抽出した。キシレ
ン層からキシレンを150g留去して残りの溶液か
らトラピジルを晶析させたところ、無色の結晶と
してトラピジルが32g得られた。このものの純度
は99.2%であり吸光度E5%
1cm(427nm)は0.030
であつた。[Table] Example 10 Crude Trapidil [E0.667 1cm (427nm) 1.00]
When 50 g of the solution was dissolved in 100 g of water, 5.0 g of NaHSO 3 was added, and the mixture was stirred at 80° C. for 5.0 hours, the absorbance E0.667 of this solution at 1 cm (427 nm) was reduced to 0.220. Next, 200 g of xylene was added and extracted at 80°C. When 150 g of xylene was distilled off from the xylene layer and trapidil was crystallized from the remaining solution, 32 g of trapidil was obtained as colorless crystals. The purity of this substance is 99.2% and the absorbance E5% 1cm (427nm) is 0.030
It was hot.
Claims (1)
−トリアゾロ〔1,5−a〕ピリミジンと還元作
用を有する硫黄化合物とを、水の存在下に接触さ
せることを特徴とする該化合物の精製法。[Claims] 1. Crude 5-methyl-7-diethylamino-s
- A method for purifying a triazolo[1,5-a]pyrimidine and a sulfur compound having a reducing action in the presence of water.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13796482A JPH0237358B2 (en) | 1982-08-10 | 1982-08-10 | 55MECHIRUU77JECHIRUAMINOOSSTORIAZORO * 1 * 55A * PIRIMIJINNOSEISEIHO |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP13796482A JPH0237358B2 (en) | 1982-08-10 | 1982-08-10 | 55MECHIRUU77JECHIRUAMINOOSSTORIAZORO * 1 * 55A * PIRIMIJINNOSEISEIHO |
Publications (2)
Publication Number | Publication Date |
---|---|
JPS5929691A JPS5929691A (en) | 1984-02-16 |
JPH0237358B2 true JPH0237358B2 (en) | 1990-08-23 |
Family
ID=15210841
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP13796482A Expired - Lifetime JPH0237358B2 (en) | 1982-08-10 | 1982-08-10 | 55MECHIRUU77JECHIRUAMINOOSSTORIAZORO * 1 * 55A * PIRIMIJINNOSEISEIHO |
Country Status (1)
Country | Link |
---|---|
JP (1) | JPH0237358B2 (en) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02182955A (en) * | 1988-12-28 | 1990-07-17 | Three D Konpo Res:Kk | Unit for regulating cloth fell of machine for weaving three-dimensional fabric |
CN107056787B (en) * | 2016-12-29 | 2019-02-05 | 大桐制药(中国)有限责任公司 | The synthesis technology of trapidil |
-
1982
- 1982-08-10 JP JP13796482A patent/JPH0237358B2/en not_active Expired - Lifetime
Also Published As
Publication number | Publication date |
---|---|
JPS5929691A (en) | 1984-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RO107257B1 (en) | Preparation process of a crystalline azitromicine dihydrate | |
JPS6123192B2 (en) | ||
CA2416792A1 (en) | Crystalline and pure modafinil, and process of preparing the same | |
CZ350596A3 (en) | PROCESS FOR PREPARING N-£3-(CYANOPYRAZOLO£1,5-a|PYRIMIDIN-7-YL)PHENYL|-N-ETHYLACETAMIDE | |
EP0208948B1 (en) | A method for optical resolution of phenylacetic acid derivative | |
DE1930118A1 (en) | Novel cephalosporin compounds and processes for their preparation | |
NZ211509A (en) | Ceftazidime bishydrobromide and pharmaceutical compositions | |
EP0118196B1 (en) | Process for the manufacture of highly crystalline sodium cefoperazone | |
JPH0237358B2 (en) | 55MECHIRUU77JECHIRUAMINOOSSTORIAZORO * 1 * 55A * PIRIMIJINNOSEISEIHO | |
US4904776A (en) | Method for producing crystalline cefadroxil hemihydrate | |
CA1219587A (en) | Hydroxybenzylaminobenzenes as anti-inflammatory agents | |
JPH11501023A (en) | Clavulanate | |
KR100336247B1 (en) | 7- [7- (S) -amino-5-azaspiro [2,4] heptan-5-yl] -8-chloro-6-fluoro-1-[(1R, 2S) -2-fluorocyclo Propyl] -4-oxo-1,4-dihydroquinoline-3-carboxylic acid anhydride, and its method of obtaining a trihydrate thereof | |
EP1138674A1 (en) | Crystalline forms of 3-(2,4-dichlorobenzyl)-2-methyl-n-(pentylsulfonyl)-3h-benzimidazole-5-carboxamide | |
JPS6157302B2 (en) | ||
JPH03240793A (en) | Purification of anfotelycine b and composition | |
US6153765A (en) | Process for producing and method of crystallizing 2-azabicyclo(2.2.1)hept-5-en-3-one | |
KR100199066B1 (en) | New salts derived from dialkylaminoalkylsulphonyl-26 pristinamycin iib | |
US4246259A (en) | Higher alkyl diaryl sulfonium salts | |
EP1004591B1 (en) | Process for preparing roxithromycin and derivatives thereof | |
EP0009996B1 (en) | Preparation of vindesine monosulfate | |
JPH0157115B2 (en) | ||
JPH0665254A (en) | Ceforanide derivative | |
JPS5939896A (en) | Purification of 5-methyl-7-diethylamino-s-triazolo (1,5-a) pyrimidine | |
IE42625B1 (en) | Thiazole-5-methanol derivatives |